Etravirine: a guide to its use in treatment-experienced pediatric patients with HIV-1 infection in the US.

Etravirine (Intelence®), an oral next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), is approved for the treatment of HIV-1 infection in treatment-experienced patients. In the US, the approved use of etravirine in patients who have evidence of viral replication and harbor HIV-1 strains resistant to other antiretroviral agents has recently been expanded to include pediatric patients aged ≥ 6 to <18 years. At 24 and 48 weeks in an open-label trial, etravirine 5.2 mg/kg twice daily (maximum dosage 200 mg twice daily) plus an optimized background therapy regimen achieved complete viral response (defined as HIV-1 RNA <50 copies/mL) in approximately half of treatment-experienced children and adolescents with HIV-1 infection and evidence of viral replication, and had an acceptable tolerability profile.
AuthorsKatherine A Lyseng-Williamson
JournalPaediatric drugs (Paediatr Drugs) Vol. 14 Issue 5 Pg. 345-50 (Oct 1 2012) ISSN: 1179-2019 [Electronic] New Zealand
PMID22897163 (Publication Type: Journal Article)
Chemical References
  • Anti-HIV Agents
  • Pyridazines
  • Reverse Transcriptase Inhibitors
  • etravirine
  • Adolescent
  • Anti-HIV Agents (administration & dosage, pharmacology, therapeutic use)
  • Child
  • Drug Therapy, Combination
  • HIV Infections (drug therapy, virology)
  • HIV-1 (drug effects, genetics)
  • Humans
  • Pyridazines (administration & dosage, adverse effects, therapeutic use)
  • Reverse Transcriptase Inhibitors (administration & dosage, adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: